Limited Access to Intraoperative Radiation Therapy (IORT) for Breast Cancer in the US

Intraoperative Radiation Therapy (IORT) Overview

• 💡 Intraoperative radiation therapy (IORT) is a promising breast cancer treatment that involves a single dose of radiation given at the time of surgery.
• 🎯 It is described as faster, less invasive, and in many cases cheaper than traditional treatments.
• 🌍 IORT is common in Europe and Asia, but its access in the United States remains limited.

Barriers to IORT Access in the US

• 💰 Critics suggest that money-minded hospitals, pharmaceuticals, and insurers may favor costlier, drawn-out treatments over the less expensive IORT.
• ⚠️ Some insurers still classify IORT as experimental, despite it being FDA approved since the 1990s.
• 📉 Hospitals may also make more money from multisession radiation treatments.

Professional Recommendations and Debate

• 🔬 The American Society for Radiation Oncology (ASTRO) does not widely recommend IORT, primarily citing concerns about cancer reoccurrence rates.
• 🗣️ However, some argue that American women are being denied this treatment compared to international standards, with claims of more access in the US than critics suggest.
• 📈 The NIH warns that without ASTRO support, the expansion of IORT use could be doomed, potentially causing a regression in US breast cancer treatment innovation.

Patient Experience and Navigation

• 🤯 Some breast cancer patients find the minefield of treatment choices and insurance coverage to be exhausting and difficult to navigate.
• 🤝 Even with premier benefits, navigating drug protocols and treatment plans often feels like a constant negotiation.
• 📌 Many women feel caught between medically possible treatments and what is covered by insurance.